loader
Please Wait
Applying Filters...
Close
4

Farmak Tafamidis Meglumine Farmak Tafamidis Meglumine

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Tafamidis Meglumine, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Tafamidis Meglumine

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass

    PharmaCompass Sponsored Ads

    PharmaCompass Sponsored Ads

    2D Structure
    1. Also known as: Vyndaqel, 951395-08-7, Fx-1006a, Fx1006a, Fx 1006a, Zu7cf08a1a
    Molecular Formula
    C21H24Cl2N2O8
    Molecular Weight
    503.3  g/mol
    InChI Key
    DQJDBUPLRMRBAB-WZTVWXICSA-N
    FDA UNII
    ZU7CF08A1A
    Tafamidis Meglumine is a soft gelatin capsule formulation containing the meglumine salt form of tafamidis, a small molecule and pharmacological chaperone with potential disease-modifying activity. Tafamidis binds to and stabilizes wild-type and variant (V122I) transthyretin (TTR), thereby preventing tetramer dissociation into monomers; this prevents misfolding of the TTR protein and inhibits the formation of TTR amyloid fibrils and the subsequent deposition of these insoluble protein clusters in peripheral nerve tissues and organs. TTR is a 127 amino acid transport protein for thyroxine and retinol and is secreted by the liver.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
    2.1.2 InChI
    InChI=1S/C14H7Cl2NO3.C7H17NO5/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-6H,(H,18,19);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1
    2.1.3 InChI Key
    DQJDBUPLRMRBAB-WZTVWXICSA-N
    2.1.4 Canonical SMILES
    CNCC(C(C(C(CO)O)O)O)O.C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl
    2.1.5 Isomeric SMILES
    CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    ZU7CF08A1A
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Fx 1006a

    2. Fx-1006a

    3. Fx1006a

    4. Tafamidis

    5. Vyndamax

    6. Vyndaqel

    2.3.2 Depositor-Supplied Synonyms

    1. Vyndaqel

    2. 951395-08-7

    3. Fx-1006a

    4. Fx1006a

    5. Fx 1006a

    6. Zu7cf08a1a

    7. Chebi:79345

    8. 951395-08-7 (meglumine)

    9. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylate

    10. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic Acid

    11. Unii-zu7cf08a1a

    12. Tafamidis Meglumine [usan]

    13. Tafamidis Meglumine [usan:inn]

    14. Vyndaqel (tn)

    15. Chembl2105675

    16. Schembl14783506

    17. Tafamidis Meglumine [mi]

    18. Tafamidis Meglumine (jan/usan)

    19. Dtxsid50915094

    20. Tafamidis Meglumine [jan]

    21. Ex-a3550

    22. Hy-14852a

    23. Mfcd28502032

    24. Tafamidis Meglumine [who-dd]

    25. Akos037649321

    26. At18247

    27. D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate

    28. Tafamidis Meglumine [orange Book]

    29. Bs-18043

    30. Cs-0045567

    31. Pf-06291826

    32. D09674

    33. Q27148396

    34. 1-deoxy-1-(methylazaniumyl)-d-glucitol 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylate

    35. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid--1-deoxy-1-(methylamino)-d-glucitol (1/1)

    36. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid--1-deoxy-1-(methylamino)hexitol (1/1)

    37. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol

    38. D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)

    39. D-gluco-2,3,4,5,6-pentahydroxy-n-methylhexan-1-aminium 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylate

    2.4 Create Date
    2008-10-20
    3 Chemical and Physical Properties
    Molecular Weight 503.3 g/mol
    Molecular Formula C21H24Cl2N2O8
    Hydrogen Bond Donor Count7
    Hydrogen Bond Acceptor Count10
    Rotatable Bond Count8
    Exact Mass502.0909711 g/mol
    Monoisotopic Mass502.0909711 g/mol
    Topological Polar Surface Area177 Ų
    Heavy Atom Count33
    Formal Charge0
    Complexity506
    Isotope Atom Count0
    Defined Atom Stereocenter Count4
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    Investigated for use/treatment in amyloidosis.

    Neuropathic heredofamilial amyloidosis

    5 Pharmacology and Biochemistry
    5.1 Mechanism of Action

    Fx-1006A is a first-in-class, disease-modifying compound that is designed to inhibit the formation of amyloid deposits by preventing the misfolding and deposition of the transthyretin protein (TTR), which is associated with amyloidosis.

    Post Enquiry
    POST ENQUIRY